The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.

A solid reagent containment unit is formed by a support; a frame body fixed to the support and delimiting internally, together with the support, an analysis volume; a reagent-adhesion structure within the analysis volume; and at least one reagent cavity, which extends within the reagent-adhesion structure. The reagent-adhesion structure is of an adhesion material embossable at temperatures lower by 6-8° C. than its own melting point and has a melting point such as not to interfere with the analysis. The reagent cavity forms a retention wall, laterally surrounding the reagent cavity, and houses dried reagents. The adhesion material is chosen among wax, such as paraffin, a polymer, such as polycaprolactone, a solid fat, such as cocoa butter, and a gel, such as hydrogel or organogel.

The present invention provides methods and composition suitable for stabilizing cell-containing samples such as blood samples. The stabilizers used are primary or secondary carboxylic acid amides.

Described herein is method for purifying messenger RNA (mRNA) encoding a DNA endonuclease from a sample, the method comprising: (a) loading the sample comprising the mRNA onto a monolithic matrix comprising a poly(dT) or poly(U) nucleic acid molecule linked/coupled to the monolithic matrix under conditions allowing the mRNA to hybridize with the poly(dT) or poly(U) nucleic acid molecule; (b) eluting the mRNA from the monolith matrix after one or more contaminants have been separated from the bound mRNA; and (c) separating the mRNA from dsRNA by adsorption chromatography, thereby resulting in a purified mRNA solution.

Temporal variations in one or more characteristics measured from a cell-free DNA sample are used to estimate a gestational age of a fetus. Example characteristics include the methylation level measured from the cell-free DNA sample, size of DNA fragments measured from the cell-free DNA sample (e.g., proportion of fetal-derived DNA fragments longer than a specified size), and ending patterns of the DNA fragments align to a reference genome.

The invention discloses an indel molecular marker closely linked with pumpkin photoperiod insensitivity and application of the indel molecular marker, and belongs to the technical field of molecule detection. The indel molecular marker SEQ7593 is located on a tenth chromosome of a Cucurbita moschata, and is 280 bp in size. The nucleotide sequence of the indel molecular marker is shown as SEQ ID NO: 1. The indel molecular marker SEQ7593 can be directly used for creating an assistant breeding system of photoperiod insensitivity character molecular markers. Primer amplification designed according to the Indel molecular marker can be applied to assistant breeding of pumpkin breed improvement molecules in a simple, rapid and high-throughput manner, technical support is provided for pumpkin photoperiod insensitivity molecular breeding, and time for conventional gene positioning is shortened greatly.

Methods and kits for isolation of cell-derived vesicles and their associated macromolecules like nucleic acids, proteins, lipids metabolites etc. from one or more blood, serum, plasma, saliva, urine, cerebrospinal fluid, breast milk, tear, conditioned culture media etc. to assist detection, prevention, and understanding of disease biology. The invention offers various advantages including simple technical solutions which are cost-effective, time-saving and scalable for large industrial outputs.

The present invention provides an extraction cassette, which includes an extraction module and a liquid receiving module. The liquid receiving module communicates with the extraction module. The liquid receiving module includes a receiving module body, a sample compartment, a sealing member, an alcohol compartment and a first path. The receiving module body includes a first side, a second side and a sample feeding hole. The sample compartment is formed on the receiving module body. The sample compartment communicates with the sample feeding hole, the sample compartment includes a first sample compartment connection hole and a second sample compartment connection hole. The sealing member is adapted to seal the sample feeding hole. The alcohol compartment is formed on the receiving module body. The alcohol compartment communicates with the first sample compartment connection hole of the first sample compartment via the first path.

The present invention relates to compositions and methods for preserving and extracting nucleic acids from saliva. The compositions include a chelating agent, a denaturing agent, buffers to maintain the pH of the composition within ranges desirable for DNA and/or RNA. The compositions may also include a reducing agent and/or antimicrobial agent. The invention extends to methods of using the compositions of the invention to preserve and isolate nucleic acids from saliva as well as to containers for the compositions of the invention.

Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8.sup.+CD39.sup.+CD103.sup.+ T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8.sup.+CD39.sup.+CD103.sup.+ T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8.sup.+CD39.sup.+CD103.sup.+ T cells. In addition, methods are disclosed for expanding CD8.sup.+CD39.sup.+CD103.sup.+ T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8.sup.+CD39.sup.+CD103.sup.+ T cells in a biological sample from a subject.